| Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation CD Rolfo, RW Madison, LW Pasquina, DW Brown, Y Huang, JD Hughes, ... Clinical Cancer Research 30 (11), 2452-2460, 2024 | 2 | 2024 |
| Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma MC Andrews, G Li, RP Graf, VA Fisher, J Mitchell, A Aboosaiedi, ... JCO Precision Oncology 8, e2300640, 2024 | | 2024 |
| Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. TF Burns, KH Dragnev, Y Fujiwara, YR Murciano-Goroff, DH Lee, ... Journal of Clinical Oncology 42 (16_suppl), 8510-8510, 2024 | | 2024 |
| Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. RS Heist, T Koyama, YR Murciano-Goroff, A Hollebecque, PA Cassier, ... Journal of Clinical Oncology 42 (16_suppl), 3007-3007, 2024 | | 2024 |
| Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data MJ Emmett, JCF Quintanilha, RP Graf, G Li, H Tukachinsky, AB Schrock, ... ESMO Real World Data and Digital Oncology 4, 100036, 2024 | | 2024 |
| Liquid biopsy‐based circulating tumour (ct) DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results DA Mata, JK Lee, V Shanmugam, CB Marcus, AB Schrock, EA Williams, ... Histopathology 84 (7), 1224-1237, 2024 | | 2024 |
| Abstract PO2-16-03: ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC) H McArthur, H Tukachinsky, A Schrock, R Madison, O Holmes, ... Cancer Research 84 (9_Supplement), PO2-16-03-PO2-16-03, 2024 | | 2024 |
| Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR (+) HER2 (-) patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for … M Bhave, J Quintanilha, R Graf, T Scott, H Tukachinsky, G Li, A Schrock, ... Cancer Research 84 (9_Supplement), PO2-16-05-PO2-16-05, 2024 | | 2024 |
| Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC) AC Chiang, RW Madison, Y Huang, A Fine, DX Jin, GR Oxnard, J Hughes, ... Cancer Research 84 (6_Supplement), 971-971, 2024 | | 2024 |
| Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non–Small-Cell Lung Cancer J Yorio, KT Lofgren, JK Lee, K Tolba, GR Oxnard, AB Schrock, ... JCO Precision Oncology 8, e2300292, 2024 | | 2024 |
| Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer B Miron, G Li, JCF Quintanilha, A Clark, T Scott, JS Ross, GR Oxnard, ... ESMO Real World Data and Digital Oncology 3, 100004, 2024 | 1 | 2024 |
| Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC PC Mack, RB Keller-Evans, G Li, KT Lofgren, AB Schrock, SE Trabucco, ... The Oncologist, oyae028, 2024 | | 2024 |
| Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types PM Kasi, JK Lee, LW Pasquina, B Decker, P Vanden Borre, DC Pavlick, ... Clinical Cancer Research 30 (4), 836-848, 2024 | 7 | 2024 |
| Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma L Burns, H Tukachinsky, K Raskina, RSP Huang, AB Schrock, J Sands, ... Lung Cancer 188, 107454, 2024 | | 2024 |
| Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib JK Rotow, JK Lee, RW Madison, GR Oxnard, PA Jänne, AB Schrock Journal of Thoracic Oncology 19 (2), 227-239, 2024 | 7 | 2024 |
| Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal … CM Parseghian, JK Lee, J Quintanilha, AB Schrock, R Graf, L Pasquina, ... Journal of Clinical Oncology 42 (3_suppl), 199-199, 2024 | | 2024 |
| POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI). RB Keller, Z Fleischmann, S Sivakumar, R Sharaf, T Janovitz, AB Schrock, ... Journal of Clinical Oncology 42 (3_suppl), 194-194, 2024 | | 2024 |
| Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases A Desai, LW Pasquina, C Nulsen, RB Keller-Evans, DA Mata, ... The Journal of Liquid Biopsy, 100140, 2024 | | 2024 |
| Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment A Russo, JK Lee, LW Pasquina, M Del Re, HH Dilks, K Murugesan, ... JCO Precision Oncology 8, e2300535, 2024 | | 2024 |
| Germline EGFR Mutations and Familial Lung Cancer GR Oxnard, R Chen, JC Pharr, DR Koeller, AA Bertram, SE Dahlberg, ... Journal of Clinical Oncology 41 (34), 5274-5284, 2023 | 13 | 2023 |
